Program Specialties

Minimally Invasive Surgery

Many patients in need of surgery of the lung are referred for a minimally invasive surgery, known as a video-assisted thoracoscopic surgery (VATS), which is done through several small incisions, versus a major chest incision, and requires no rib spreading. The large majority of all lung cancer patients in need of surgery at Smilow Cancer Hospital are scheduled for a VATS procedure.

Robotic Surgery

The da Vinci Robotic System for surgery has provided patients with prostate cancer and gynecological cancers less invasive surgical options with decreased side effects. Now, utilizing the da Vinci System, thoracic robotic surgery is available at Smilow Cancer Hospital at Yale-New Haven for patients with lung cancer.

Stereotactic Body Radiotherapy

A non-invasive technique, stereotactic body radiotherapy (SBRT) was introduced at Yale in 2007 to provide extremely high doses of radiation with a high level of accuracy to lung cancer tumors. This precise treatment also results in less radiation delivered to surrounding tissue and fewer side effects.

Thoracic Interventional Program

The Thoracic Interventional Program (TIP) is a joint program between pulmonary/critical care medicine and thoracic surgery at Smilow Cancer Hospital. This collaboration combines advanced, state-of-the-art technology with physicians dedicated to the evaluation and treatment of patients with lung diseases.

HALO Ablation Therapy

HALO Ablation Therapy is used for patients diagnosed with Barrett’s esophagus to remove diseased or pre-cancerous tissue in the esophagus. Performed in conjunction with an upper endoscopy, ablation is a technique where tissue is heated to precisely destroy the diseased tissue in a highly controlled manner.

Lung Screening and Nodule Program

The Yale Lung Screening and Nodule Program is dedicated to providing individuals who are at risk for developing lung cancer with individualized, evidence-based care. Screening for lung cancer is a new clinical practice that is based on the results from the National Lung Cancer Screening Trial (NLST) and years of clinical research. The NLST demonstrates that, in certain people, a well-organized approach to screening can prevent 1 in 5 deaths from lung cancer.

Linda: Lung Cancer Survivor

Linda Yuhas

In May of 2007, I was diagnosed with lymphoma. Shortly after, while testing was being done to stage the lymphoma, two small tumors were discovered on my lungs. My first reaction was tears. It seemed as though with every passing day my results got worse and worse. Then my doctor recommended that I see Dr. Scott Gettinger, Assistant Professor of Medical Oncology at Yale School of Medicine and a member of the Yale Cancer Center Thoracic Oncology Program.

Contact Us

(203) 200-5864

Clinical Program Leader:
Frank C. Detterbeck, MD

Translational Working Group Leader:
Roy S. Herbst, MD, PhD